Following a structured meal plan that includes lean proteins, fiber-rich vegetables, and healthy fats can improve results while reducing the risk of weight gain
Do not take Qsymia if you are pregnant, planning to become pregnant, or become pregnant during Qsymia treatment
Gallbladder problems, like gallstones, go up modestly, partly because rapid weight loss itself raises that risk
Jumpstart your successclick to learn more
Eli Lilly now sells Zepbound, its tirzepatide obesity drug, directly to consumers for $349 or $499 per month, depending on the dose
Projected Timeline (Estimates, Not Confirmed) Phase 3 completion: Most TRIUMPH trials completing throughout 2026 NDA submission to FDA: Estimated late 2026 (depends on results across the full program) FDA review period: Typically 10-12 months for a standard review Approval decision: Estimated 2027, possibly earlier if Lilly seeks priority review Commercial availability (pharmacies): Several months after approval for manufacturing scale-up GlobalData, a pharmaceutical analytics firm, projects a 2027 approval with forecasted annual sales reaching $15.6 billion by 2031
